Beyond VEGF: Angiopoietin–Tie Signaling Pathway in Diabetic Retinopathy

作者
Genesis Chen-Li,Rebeca Martinez-Archer,Andrés Coghi Brenes,José Antonio Roca,Francisco J. Rodríguez,Luis A. Acaba-Berrocal,María H. Berrocal,Lihteh Wu
出处
期刊:Journal of Clinical Medicine [Multidisciplinary Digital Publishing Institute]
卷期号:13 (10): 2778-2778 被引量:34
标识
DOI:10.3390/jcm13102778
摘要

Complications from diabetic retinopathy such as diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR) constitute leading causes of preventable vision loss in working-age patients. Since vascular endothelial growth factor (VEGF) plays a major role in the pathogenesis of these complications, VEGF inhibitors have been the cornerstone of their treatment. Anti-VEGF monotherapy is an effective but burdensome treatment for DME. However, due to the intensive and burdensome treatment, most patients in routine clinical practice are undertreated, and therefore, their outcomes are compromised. Even in adequately treated patients, persistent DME is reported anywhere from 30% to 60% depending on the drug used. PDR is currently treated by anti-VEGF, panretinal photocoagulation (PRP) or a combination of both. Similarly, a number of eyes, despite these treatments, continue to progress to tractional retinal detachment and vitreous hemorrhage. Clearly there are other molecular pathways other than VEGF involved in the pathogenesis of DME and PDR. One of these pathways is the angiopoietin-Tie signaling pathway. Angiopoietin 1 (Ang1) plays a major role in maintaining vascular quiescence and stability. It acts as a molecular brake against vascular destabilization and inflammation that is usually promoted by angiopoietin 2 (Ang2). Several pathological conditions including chronic hyperglycemia lead to Ang2 upregulation. Recent regulatory approval of the bi-specific antibody, faricimab, may improve long term outcomes in DME. It targets both the Ang/Tie and VEGF pathways. The YOSEMITE and RHINE were multicenter, double-masked, randomized non-inferiority phase 3 clinical trials that compared faricimab to aflibercept in eyes with center-involved DME. At 12 months of follow-up, faricimab demonstrated non-inferior vision gains, improved anatomic outcomes and a potential for extended dosing when compared to aflibercept. The 2-year results of the YOSEMITE and RHINE trials demonstrated that the anatomic and functional results obtained at the 1 year follow-up were maintained. Short term outcomes of previously treated and treatment-naive eyes with DME that were treated with faricimab during routine clinical practice suggest a beneficial effect of faricimab over other agents. Targeting of Ang2 has been reported by several other means including VE-PTP inhibitors, integrin binding peptide and surrobodies.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
传奇3的应助被科研通管家采纳,获得10
刚刚
我是谁的应助被科研通管家采纳,获得30
1秒前
小马甲的应助被科研通管家采纳,获得10
1秒前
专注寻菱完成签到,获得积分10
1秒前
金勇完成签到,获得积分10
1秒前
魁梧的黑猫完成签到,获得积分10
1秒前
1秒前
我是谁的应助被科研通管家采纳,获得20
1秒前
啦啦啦完成签到,获得积分10
1秒前
LEO2025完成签到,获得积分10
1秒前
禾斗完成签到,获得积分10
1秒前
cz发布了新的文献求助10
1秒前
SciGPT的应助被科研通管家采纳,获得10
1秒前
SciGPT的应助被怡然浩阑采纳,获得10
1秒前
迷人雪一完成签到,获得积分10
1秒前
火星上行云完成签到,获得积分20
2秒前
典雅雁梅发布了新的文献求助10
2秒前
lucky完成签到,获得积分10
2秒前
奥利奥扭不开怎么办完成签到,获得积分10
3秒前
鸣熠完成签到,获得积分10
3秒前
davyean完成签到,获得积分10
3秒前
release完成签到 ,获得积分10
3秒前
烟花的应助被凌翎采纳,获得10
4秒前
Demons完成签到,获得积分10
4秒前
Amy完成签到,获得积分10
4秒前
4秒前
秉一完成签到 ,获得积分10
4秒前
基金中中中完成签到,获得积分10
5秒前
思源的应助被yhq采纳,获得10
5秒前
小胖卷毛完成签到,获得积分10
6秒前
lejunia完成签到,获得积分10
6秒前
冷静雪糕完成签到,获得积分10
6秒前
火星上的白翠完成签到 ,获得积分10
6秒前
zmh完成签到 ,获得积分10
6秒前
CharlieYue完成签到,获得积分10
7秒前
JXDYYZK完成签到,获得积分0
7秒前
赘婿的应助被荷序采纳,获得10
7秒前
乐乐的应助被酷酷柚子采纳,获得10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173474
求助须知:如何正确求助?哪些是违规求助? 9565719
关于积分的说明 21781727
捐赠科研通 7767700
什么是DOI,文献DOI怎么找? 3431597
关于科研通互助平台的介绍 2555855
邀请新用户注册赠送积分活动 2476832